Promising Therapeutic Effect of Gold Nanoparticles Against Dinitrobenzene Sulfonic Acid-Induced Colitis in Rats

Hussein, Rehab M.; Saleh, Hanan

doi:10.2217/nnm-2018-0009

Cited by 19 publications

(9 citation statements)

References 86 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A study by Hussein et al [ 131 ] investigated the treatment potential of intravenously administrated GNPs at various sizes (16–25 nm) and doses (40 and 400 μg/kg) in experimental colitis. These data showed that GNP treatments suppressed the inflammatory response by decreasing the pro-inflammatory cytokine levels, including TNF-α and IL-6, which eventually reduced the colon inflammation and diminished the oxidative stress markers.…”

Section: Application Of Gnps In Other Autoimmune Diseasesmentioning

confidence: 99%

Gold Nanoparticles: Multifaceted Roles in the Management of Autoimmune Disorders

et al. 2021

View full text Add to dashboard Cite

Gold nanoparticles (GNPs) have been recently applied for various diagnostic and therapeutic purposes. The unique properties of these nanoparticles (NPs), such as relative ease of synthesis in various sizes, shapes and charges, stability, high drug-loading capacity and relative availability for modification accompanied by non-cytotoxicity and biocompatibility, make them an ideal field of research in bio-nanotechnology. Moreover, their potential to alleviate various inflammatory factors, nitrite species, and reactive oxygen production and the capacity to deliver therapeutic agents has attracted attention for further studies in inflammatory and autoimmune disorders. Furthermore, the characteristics of GNPs and surface modification can modulate their toxicity, biodistribution, biocompatibility, and effects. This review discusses in vitro and in vivo effects of GNPs and their functionalized forms in managing various autoimmune disorders (Ads) such as rheumatoid arthritis, type 1 diabetes, and multiple sclerosis.

show abstract

Section: Application Of Gnps In Other Autoimmune Diseasesmentioning

confidence: 99%

Gold Nanoparticles: Multifaceted Roles in the Management of Autoimmune Disorders

et al. 2021

View full text Add to dashboard Cite

show abstract

“…These results confirmed our investigations that applying GNPs to IA delivery was a potential technique for improving treatment efficacy and compliance in patients with RA [ 26 ], where GNPs appeared to block production of proinflammatory IL-6 cytokines in Jurkat and U937 cells due to a decrease in phosphorylation of extracellular signal-regulated kinases (ERK). In addition, previous results illustrated that coupling with GNPs could add an immunomodulatory function to the conjugated drug by impairing the production of pro-inflammatory cytokines [ 27 ]. Moreover, a previous review had shown an increase in anti-inflammatory cytokine IL-10 secretion from macrophages, in a dose dependent manner of GNPs, in the hepatic injury rat model [ 28 ].…”

Section: Discussionmentioning

confidence: 99%

Nano Methotrexate versus Methotrexate in Targeting Rheumatoid Arthritis

et al. 2022

View full text Add to dashboard Cite

Nanomedicine has emerged as an important approach for targeting RA medication. Rheumatoid arthritis (RA) is a widespread autoimmune disorder marked by multiple inflamed joints. Gold nanoparticles (GNPs) have been demonstrated as efficacious nanocarriers due to their unique characteristics and the relative simplicity of their synthesis in varied sizes; moreover, they have the capability to alleviate several inflammatory markers. The current objective was to combine methotrexate (MTX) with GNPs to overcome MTX restrictions. GNPs were fabricated by a chemical reduction technique, utilizing sodium citrate and tween 20. The MTX-GNPs formulations were characterized in vitro by % entrapment efficiency (%EE), particle size, polydispersity index (PDI) zeta potential, and % release. The MTX-GNPs formulation was administrated as an intra-articular solution, and additionally, incorporated into a Carbopol gel to investigate its anti-arthritic effectiveness and bioavailability in vivo. The results indicated that a %EE of 87.53 ± 1.10%, and a particle size of 60.62 ± 2.41 nm with a PDI of 0.31 ± 0.03, and a zeta potential of −27.80 ± 0.36 mV were optimal. The in vitro release of MTX from the MTX-GNPs formulation demonstrated that the MTX-GNPs formulation’s release was 34.91± 1.96% and considerably (p < 0.05) lower than that of free MTX, showing a significant difference in dissolution patterns (p < 0.05). In vivo, MTX-GNPs formulations inhibited IL-6 by 36.52%, ACCP (63.25 %), COMP (28.16%), and RANKL (63.67%), as well as elevated IL-10 by 190.18%. Transdermal MTX-GNPs decreased IL-6 by 22.52%, ACCP (56.63%), COMP (52.64%), and RANKL (79.5%), as well as increased IL-10 by 168.37%. Histological investigation supported these recent findings. Conclusions: Marked improvements in MTX anti-arthritic effects are seen when it is conjugated to GNPs.

show abstract

“…In this synthesis, citrate ions act as reducing agent and stabilizer (Kong et al 2017 ); furthermore, the negative charge of citrate ions repels AuNPs from each other. The size of gold nanoparticles formed depends on the sodium citrate concentration, salt of gold, temperature, and boiling duration (Hussein and Saleh 2018 ).…”

Section: Methodsmentioning

confidence: 99%

Polyethylene glycol capped gold nanoparticles ameliorate renal ischemia–reperfusion injury in diabetic mice through AMPK-Nrf2 signaling pathway

Saleh

Salama

Hussein

2022

Environ Sci Pollut Res

View full text Add to dashboard Cite

The aim of this study is to investigate the protective effect of polyethylene glycol capped gold nanoparticles (PEG-AuNPs) on renal ischemia–reperfusion injury (I/R)–induced acute kidney injury (AKI) in diabetic mice via the activation of adenosine 5′ monophosphate–activated protein kinase—nuclear factor erythroid-2-related factor-2 (AMPK-Nrf2) pathway. Diabetes was induced in male mice (12/group) by streptozotocin (50 mg/kg) for 5 consecutive days. After 4 weeks, the mice have intravenously received doses of PEG-AuNPs (40, 150, and 400 µg/kg body weight) for 3 consecutive days, and then animals were subjected to 30 min ischemia and 48 h reperfusion. Following the treatment with three different doses of PEG-AuNPs, the levels of blood urea nitrogen (BUN) and creatinine were reduced. Obvious reduction in renal tubular atrophy, glomerular damage, mitochondrial damage, and necrotic area were ultra-structurally detected, and renal interstitial inflammation and apoptosis were diminished. Moreover, PEG-AuNPs increased the recovering of damaged renal cells, suppressed significantly levels of malondialdehyde (MDA), downregulated significantly the level of inflammatory cytokines (TNF-α and IL-1β), and upregulated the AMPK-Nrf2 pathway. PEG-AuNPs exhibited a promising alternative therapeutic target for diabetic renal I/R-induced AKI through upregulation of AMPK/PI3K/AKT path which additionally stimulated Nrf2-regulated antioxidant enzymes in a dose-dependent manner. Graphical abstract

show abstract

Promising Therapeutic Effect of Gold Nanoparticles Against Dinitrobenzene Sulfonic Acid-Induced Colitis in Rats

Abstract: Our study suggested a new therapy for experimental colitis without noticeable drawbacks.

Cited by 19 publications

References 86 publications

Gold Nanoparticles: Multifaceted Roles in the Management of Autoimmune Disorders

Gold Nanoparticles: Multifaceted Roles in the Management of Autoimmune Disorders

Nano Methotrexate versus Methotrexate in Targeting Rheumatoid Arthritis

Polyethylene glycol capped gold nanoparticles ameliorate renal ischemia–reperfusion injury in diabetic mice through AMPK-Nrf2 signaling pathway

Contact Info

Product

Resources

About